DR. YOUNG JOO LEE M.D.
Prescription History 1528036498
Internal Medicine - Hematology & Oncology in Charleston, SC

NPI Status: Active since March 08, 2006

Contact Information

171 ASHLEY AVE
CHARLESTON, SC
ZIP 29425
Phone: (843) 792-1414

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. YOUNG JOO LEE M.D., an active Hematology & Oncology specialist practicing in Charleston, SC. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 526 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 248 claims alone.


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 36.4
Days Supply 1,092
SC State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills86.3
Peer Average Days Supply2,558
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.8% less volume than the regional standard for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $256.59 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.74

State Avg Cost Per Claim

$11.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 248
30-Day Fills 730.0
Days Supply 21,855
SC State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills157.7
Peer Average Days Supply4,714
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 275.8% higher than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,957.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.09

State Avg Cost Per Claim

$27.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Exemestane

Generic Formulation: ExemestaneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 51.0
Days Supply 1,530
SC State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills51.5
Peer Average Days Supply1,528
Conservative Utilization

This provider writes prescriptions for this formulation 37.0% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,083.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$357.83

State Avg Cost Per Claim

$229.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Ibandronate Sodium

Generic Formulation: Ibandronate SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 31
30-Day Fills 91.8
Days Supply 2,754
SC State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills61.7
Peer Average Days Supply1,846
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,286.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.51

State Avg Cost Per Claim

$53.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.

Therapeutic Applications

Ibandronate is used to prevent and treat certain types of bone loss (osteoporosis). Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause, as you age, or if you take corticosteroid medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Ibandronate belongs to a class of medications called bisphosphonates.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 35
30-Day Fills 73.0
Days Supply 2,190
SC State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills133.8
Peer Average Days Supply3,991
Conservative Utilization

This provider writes prescriptions for this formulation 40.7% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $446.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.76

State Avg Cost Per Claim

$30.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Lynparza

Generic Formulation: OlaparibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
SC State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills19.4
Peer Average Days Supply579
Conservative Utilization

This provider writes prescriptions for this formulation 38.9% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $134,093.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,190.33

State Avg Cost Per Claim

$14,238.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as breast, ovarian, fallopian tube, pancreatic, peritoneal cancer, prostate). Olaparib works by slowing or stopping the growth of cancer cells.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 186
SC State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills29.6
Peer Average Days Supply401
Conservative Utilization

This provider writes prescriptions for this formulation 42.9% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $203.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.74

State Avg Cost Per Claim

$20.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Oxybutynin Chloride

Generic Formulation: Oxybutynin ChlorideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 40.0
Days Supply 1,200
SC State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills50.3
Peer Average Days Supply1,454
Conservative Utilization

This provider writes prescriptions for this formulation 46.2% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $336.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$24.05

State Avg Cost Per Claim

$23.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics. This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 248
SC State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills31.4
Peer Average Days Supply392
Conservative Utilization

This provider writes prescriptions for this formulation 38.7% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $300.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.82

State Avg Cost Per Claim

$18.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 122
30-Day Fills 357.0
Days Supply 10,702
SC State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills99.8
Peer Average Days Supply2,974
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 177.3% higher than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,018.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.94

State Avg Cost Per Claim

$31.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. YOUNG JOO LEE M.D. provides transparency into local medical care patterns within Charleston, SC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.